Helene Aschmann, PhD

Title(s)Postdoctoral Scholar, Medicine
SchoolSchool of Medicine
Address550 16th Street, #2649
San Francisco CA 94158
ORCID ORCID Icon0000-0003-1234-4321 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Zurich, Zurich, SwitzerlandPhD05/2020Epidemiology
    Swiss Federal Institute of Technology ETH Zürich, Zurich, SwitzerlandMSc04/2015Medicinal and Industrial Pharmaceutical Sciences

    Collapse Research 
    Collapse Research Activities and Funding
    Informing patient-centered care through quantitative benefit-harm assessment in latent tuberculosis
    Swiss National Science Foundation Apr 1, 2021 - Sep 30, 2022

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A Data-Driven Simulation of the Exposure Notification Cascade for Digital Contact Tracing of SARS-CoV-2 in Zurich, Switzerland. JAMA Netw Open. 2021 04 01; 4(4):e218184. Menges D, Aschmann HE, Moser A, Althaus CL, von Wyl V. PMID: 33929521; PMCID: PMC8087953.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsPHPublic Health
    2. Assessment of Patient-Preferred Language to Achieve Goal-Aligned Deprescribing in Older Adults. JAMA Netw Open. 2021 04 01; 4(4):e212633. Green AR, Aschmann H, Boyd CM, Schoenborn N. PMID: 33818621; PMCID: PMC8022217.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    3. [Cancer Screening - Prerequesites for a Successful and Meaningful Screening Program]. Ther Umsch. 2021; 78(2):55-60. Aschmann HE, Puhan MA. PMID: 33615862.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    4. Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study. BMC Cardiovasc Disord. 2020 09 17; 20(1):418. Yebyo HG, Zappacosta S, Aschmann HE, Haile SR, Puhan MA. PMID: 32942999; PMCID: PMC7495829.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    5. Benefit-harm balance of fingolimod in patients with MS: A modelling study based on FREEDOMS. Mult Scler Relat Disord. 2020 Nov; 46:102464. Spanu A, Aschmann HE, Kesselring J, Puhan MA. PMID: 32889373.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. Informing Patient-Centered Care Through Stakeholder Engagement and Highly Stratified Quantitative Benefit-Harm Assessments. Value Health. 2020 05; 23(5):616-624. Aschmann HE, Boyd CM, Robbins CW, Chan WV, Mularski RA, Bennett WL, Sheehan OC, Wilson RF, Bayliss EA, Leff B, Armacost K, Glover C, Maslow K, Mintz S, Puhan MA. PMID: 32389227.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    7. Outcome preferences of older people with multiple chronic conditions and hypertension: a cross-sectional survey using best-worst scaling. Health Qual Life Outcomes. 2019 Dec 19; 17(1):186. Aschmann HE, Puhan MA, Robbins CW, Bayliss EA, Chan WV, Mularski RA, Wilson RF, Bennett WL, Sheehan OC, Yu T, Yebyo HG, Leff B, Tabano H, Armacost K, Glover C, Maslow K, Mintz S, Boyd CM. PMID: 31856842; PMCID: PMC6924040.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    8. Net benefit of statins for primary prevention of cardiovascular disease in people 75 years or older: a benefit-harm balance modeling study. Ther Adv Chronic Dis. 2019; 10:2040622319877745. Yebyo HG, Aschmann HE, Menges D, Boyd CM, Puhan MA. PMID: 31598209; PMCID: PMC6764041.
      View in: PubMed   Mentions: 6  
    9. Balance of benefits and harms of different blood pressure targets in people with multiple chronic conditions: a quantitative benefit-harm assessment. BMJ Open. 2019 08 30; 9(8):e028438. Aschmann HE, Boyd CM, Robbins CW, Mularski RA, Chan WV, Sheehan OC, Wilson RF, Bennett WL, Bayliss EA, Yu T, Leff B, Armacost K, Glover C, Maslow K, Mintz S, Puhan MA. PMID: 31471435; PMCID: PMC6720326.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    10. Statins for Primary Prevention of Cardiovascular Disease. Ann Intern Med. 2019 07 02; 171(1):74-76. Yebyo HG, Aschmann HE, Puhan MA. PMID: 31261399.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    11. A benefit-harm analysis of adding basal insulin vs. sulfonylurea to metformin to manage type II diabetes mellitus in people with multiple chronic conditions. J Clin Epidemiol. 2019 09; 113:92-100. Bennett WL, Aschmann HE, Puhan MA, Robbins CW, Bayliss EA, Wilson R, Mularski RA, Chan WV, Leff B, Sheehan O, Glover C, Maslow K, Armacost K, Mintz S, Boyd CM. PMID: 31059802.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    12. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J. 2019 04; 210:18-28. Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA. PMID: 30716508.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    13. Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease: A Modeling Study. Ann Intern Med. 2019 01 01; 170(1):1-10. Yebyo HG, Aschmann HE, Puhan MA. PMID: 30508425.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansPHPublic Health
    14. Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts. BMC Cardiovasc Disord. 2018 05 18; 18(1):97. Yebyo HG, Aschmann HE, Yu T, Puhan MA. PMID: 29776337; PMCID: PMC5960214.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansPHPublic Health
    15. Kinetics of lipid bilayer permeation of a series of ionisable drugs and their correlation with human transporter-independent intestinal permeability. Eur J Pharm Sci. 2017 Jun 15; 104:150-161. Hermann KF, Neuhaus CS, Micallef V, Wagner B, Hatibovic M, Aschmann HE, Paech F, Alvarez-Sanchez R, Krämer SD, Belli S. PMID: 28366650.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    16. A Comparative Analysis of Drug-Induced Hepatotoxicity in Clinically Relevant Situations. PLoS Comput Biol. 2017 02; 13(2):e1005280. Thiel C, Cordes H, Fabbri L, Aschmann HE, Baier V, Smit I, Atkinson F, Blank LM, Kuepfer L. PMID: 28151932; PMCID: PMC5289425.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    17. A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy. Antimicrob Agents Chemother. 2016 10; 60(10):6134-45. Cordes H, Thiel C, Aschmann HE, Baier V, Blank LM, Kuepfer L. PMID: 27480867; PMCID: PMC5038291.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    18. When barriers ignore the "rule-of-five". Adv Drug Deliv Rev. 2016 06 01; 101:62-74. Krämer SD, Aschmann HE, Hatibovic M, Hermann KF, Neuhaus CS, Brunner C, Belli S. PMID: 26877103.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells